Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae140 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Amparo L Figueroa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: 2019-nCoV Vaccine mRNA-1273, COVID-19, COVID-19 Vaccines, Organ Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Solid organ transplant recipients (SOTRs) are at high risk for severe COVID-19.
Methods
This open-label, phase 3b trial evaluated mRNA-1273 in 137 kidney and 77 liver SOTRs and 20 immunocompetent participants. In part A, SOTRs received three 100-µg doses of mRNA-1273; immunocompetent participants received 2 doses. In part B, an additional 100-µg dose was offered ≥4 months after the primary series. Here, we report interim trial results. Results mRNA-1273 was well-tolerated in SOTRs. Four serious adverse events were considered vaccine related by the investigator in 3 SOTRs with preexisting comorbidities. No vaccine-related biopsy-proven organ rejection events or deaths were reported. mRNA-1273 elicited modest neutralizing antibody responses after dose 2 and improved responses after dose 3 in SOTRs. Post–dose 3 responses among liver SOTRs were comparable to post–dose 2 responses in immunocompetent participants. Post-additional dose responses were increased in SOTRs, regardless of primary series vaccination. In liver SOTRs, post-additional dose responses were ∼3-fold higher versus post-dose 2 but lower than immunocompetent participant responses. Most kidney SOTRs received multiple immunosuppressants and had reduced antibody responses versus liver SOTRs. Conclusions mRNA-1273 was well-tolerated, and dose 3 and the additional dose improved antibody responses among SOTRs. Clinical Trials Registration NCT04860297.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moderna, Cambridge, Massachusetts, USA.
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Cleveland Clinic, Cleveland, Ohio, USA.
Zitieren
APA
Figueroa, A. L., Azzi, J. R., Eghtesad, B., Priddy, F., Stolman, D., Siangphoe, U., Leony Lasso, I., de Windt, E., Girard, B., Zhou, H., Miller, J. M., & Das, R. (2024). Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae140
Vancouver
Figueroa AL, Azzi JR, Eghtesad B, Priddy F, Stolman D, Siangphoe U, et al. Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae140
BibTeX
@article{Figueroa2024,
author = {Figueroa, Amparo L and Azzi, Jamil R and Eghtesad, Bijan and Priddy, Frances and Stolman, Dina and Siangphoe, Uma and Leony Lasso, Iliana and de Windt, Elizabeth and Girard, Bethany and Zhou, Honghong and Miller, Jacqueline M and Das, Rituparna},
title = {Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae140}
}
EUVIMED